Experience with Blonanserin Patch for Prevention of Nausea and Vomiting during the Initiation of Continuous Subcutaneous Injection of Hydromorphone Hydrochloride in Patients with End-stage Cancer Who are Difficult to Take Internal Medication in Palliative Care Unit

DOI Web Site 7 References Open Access

Bibliographic Information

Other Title
  • 緩和ケア病棟の内服困難ながん終末期患者へのヒドロモルフォン塩酸塩持続皮下注開始時の悪心・嘔吐予防としてのブロナンセリン経皮吸収型製剤の使用経験

Search this article

Description

<p>When continuous subcutaneous injection of opioid analgesics is initiated for patients in the terminal stages of cancer who are unable to take oral medication, Haloperidol is widely used in combination to prevent nausea and vomiting. However, Haloperidol carries the risk of skin damage at the site of subcutaneous injection. Therefore, we tried to use Blonanserin patch for the prevention of nausea and vomiting during continuous subcutaneous injection of Hydromorphone hydrochloride. In the present study, we retrospectively evaluated patients who had no history of opioid analgesic use, no concomitant use of other antiemetic drugs or antipsychotics, and who were followed up for at least 1 week. In the 5 patients who used Blonanserin patch, no nausea or vomiting occurred, and there were no skin lesions at the site of Blonanserin patch application or subcutaneous injection. In 5 cases of Haloperidol with continuous subcutaneous injection, 1 patient had nausea, 2 had skin lesions at the subcutaneous puncture site. Blonanserin patch seemed to be an option for the prevention of nausea and vomiting during continuous subcutaneous injection of Hydromorphone hydrochloride in end-stage cancer patients who were hospitalized in a palliative care unit and were unable to take oral medication.</p>

Journal

References(7)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top